Highlights Newsletter 2
This newsletter presents you the following key sessions:
3. Circulating tumour cells-driven choice of first line therapy for ER+ HER2- metastatic breast cancer
This newsletter presents you the following key sessions:
3. Circulating tumour cells-driven choice of first line therapy for ER+ HER2- metastatic breast cancer
Medical writer
Medical writer
Medical writer